Profusa Raises 2026 Revenue Guidance on Strong European Demand for Lumee Tissue Oxygen System
Event summary
- Profusa received purchase orders for Lumee™ tissue oxygen monitoring system from European distributors and expert physician customers.
- 2026 revenue guidance raised to $1.5M–$3M, up from $500K–$2M.
- CE Mark approval under EU MDR expected in Q2 2026, enabling product shipments.
- Collaboration with Mayo Clinic positions potential US market entry by late 2026.
- Inventory build-up underway to support anticipated demand in Q2 2026.
The big picture
Profusa's raised revenue guidance reflects strong European demand for its Lumee tissue oxygen monitoring system, driven by positive clinical study results and anticipated regulatory approval. The company's strategic collaboration with Mayo Clinic positions it for potential US market entry, aligning with broader trends in continuous biochemistry monitoring and digital health innovation. The ability to scale operations and meet demand will be critical to sustaining this momentum.
What we're watching
- Regulatory Compliance
- Whether Profusa can finalize EU MDR compliance by Q2 2026 to fulfill purchase orders.
- Market Adoption
- The pace at which Lumee Oxygen is adopted by surgeons in Europe post-regulatory approval.
- US Market Entry
- How the collaboration with Mayo Clinic will accelerate potential US market entry by late 2026.
Related topics